Racivir
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | Investigational |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
NIAID ChemDB | |
Chemical and physical data | |
Formula | C8H10FN3O3S |
Molar mass | 247.24 g·mol−1 |
3D model (JSmol) | |
| |
|
Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1] It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.
References
- ^ "Racivir". AIDSmeds.com. March 24, 2006. Archived from the original on 2014-01-02. Retrieved March 21, 2008.
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles
- Antiinfective agent stubs
- Nucleoside analog reverse transcriptase inhibitors
- Pyrimidones
- Oxathiolanes
- Organofluorides
- Experimental antiviral drugs
- Hydroxymethyl compounds